Diego Adrianzen-Herrera, MD, MS

American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/10.1002/aj…

ICYMI: Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases brnw.ch/21wUqBg #CHIPsm #clonalhematopoiesis

🧪 MRD in AML – Techniques, Differences & Interpretation 🔍 Why MRD in AML? Measurable Residual Disease (MRD) is the most sensitive tool to detect disease persistence post-treatment. It predicts relapse, guides transplant decisions, and refines risk stratification, especially in…

Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis @LeukemiaJnl nature.com/articles/s4137…

ICYMI: Putting AML Differentiation States on the BoneMarrowMap brnw.ch/21wUj48 @livius_tacitus

MDS-EB1 and -EB2 share biological characteristics and have equally poor survival, regardless of allelic status, supporting their integration. ow.ly/I29U50WnbTv #myeloidneoplasia

🧬 MRD Monitoring in AML (Blood 2022) with Exam Pearls for Fellows 🩸 NPM1 & CBF-AML: Methods: qPCR, dPCR, NGS Timepoints: Diagnosis: BM or PB After 2 cycles: PB End of treatment: BM Follow-up: BM q3mo or PB q4-6w MRD relapse: Conversion from MRD negative ➡ MRD positive OR…

🧬 #AML Classification #ICC vs #WHO 2022 by Dr Ahmad Alhuraiji at #AIinHematology: 🔹 Both define AML with blasts <20% 🔹 CBF, NPM1: AML if blasts >10% 🔹 CEBPA-mutant: any in WHO, only bZIP in ICC 🔹 BCR::ABL1: AML if blasts >20% 🔹 ICC: AML/MDS category if blasts 10-19% 🔹…

A comprehensive review on the management of #CML in 2025 written by an international group of CML experts. @MDAndersonNews #Leukemia doi.org/10.1002/cncr.3… @JournalCancer @FadiHaddad_MD @GhayasIssa #leusm

A review of common immunotherapy and nano immunotherapy for acute myeloid leukemia frontiersin.org/journals/immun… #AML #leusm

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management onlinelibrary.wiley.com/doi/10.1002/aj… #AML #leusm

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia nature.com/articles/s4137…

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management - PubMed pubmed.ncbi.nlm.nih.gov/40253543/

Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast] - PubMed pubmed.ncbi.nlm.nih.gov/40575712/

Clinical management of CMML British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

Intermediate-Dose Cytarabine as Postinduction AML Therapy | NEJM Evidence evidence.nejm.org/doi/full/10.10…

Patients with TP53-mutated AML/MDS represent a unique and heterogeneous high-risk group that should not be treated as 1 single entity. ow.ly/tEXM50W7tLk #myeloidneoplasia #transplantation #clinicaltrialsandobservations

Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML | Journal of Clinical Oncology ascopubs.org/doi/abs/10.120…

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome are now well established as their own unique diagnostic entity, characterized by an exceptionally poor prognosis and inadequate therapeutic options. ow.ly/XMBu50WagUw #BloodSpotlight #myeloidneoplasia

“Nonclassical” myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms represent a heterogeneous group of malignancies characterized by a wide range of clinical manifestations. ow.ly/5knJ50W1ftQ #myeloidneoplasia #transplantation